Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
Enveric Biosciences Receives Patent Notice of Allowance for Novel Prodrug of Psilocin
Enveric Biosciences announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, Enveric’s new chemical entity (NCE) psilocin prodrug being developed for the treatment of anxiety disorder.
From Joseph Tucker, Director and CEO of Enveric: “The positive decision from the USPTO related to our lead candidate, EB-373 highlights the innovative designs of the psilocin prodrugs being developed as part of our EVM201 Series, and differentiations in those designs that enable our molecules to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin…”
Terran Biosciences Discovers New Psilocybin Salts and Polymorphs; Publishes Patent Application
Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA.
Dr. Sam Clark, Terran’s CEO commented, “We’re really excited about this discovery and believe that these new forms of psilocybin will significantly broaden access and improve the ability of researchers and developers to work with this compound to deliver new therapeutics. We believe this also marks a new chapter in psychedelic medicinal chemistry, in which we have worked with one of the most well-studied compounds to create novel breakthroughs previously not thought possible.”
MindMed Announces Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
MindMed announced that the company’s Phase 2b study evaluating MM-120 for GAD is over 50% enrolled and dosed. Topline results are expected to be announced in late 2023.
“We are thrilled by the quality and efficiency with which study enrollment has progressed as we approach our expected topline data release later this year. This progress is a testament to the tireless work and dedication of all the individuals executing this study and stands out as one of the fastest recruiting efforts for this class of therapies in development,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “We have seen a meaningful acceleration in enrollment over the last few months since our full set of study sites were activated early this year with 25 patients enrolled just in the last 30 days.”
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Clearmind Medicine has received notice from the NASDAQ exchange warning that the stock is below the minimum bid price of $1.00 per share. The company has until November 13th to regain compliance.